Quest Diagnostics Incorporated (DGX) stock analysis and fair value

Quest Diagnostics Incorporated key numbers

Market cap

26 B US$

P/E (price ÷ earnings)

26,9

Dividend yield

1,33%

Revenue growth

4,4%

a year, over 9 years

Profit margin

9,0%

Quality checks

4/8

Fiscal 2025 financials, as filed with the SEC.

About Quest Diagnostics Incorporated

Quest Diagnostics Incorporated, founded in 1967 and headquartered in Secaucus, New Jersey, is a premier provider of diagnostic testing, information, and related services, serving clients both domestically and internationally. Its core business involves the development and provision of diverse diagnostic information services, such as routine, advanced clinical, and anatomic pathology testing. While primarily operating under the Quest Diagnostics brand, it also leverages specialized identities like AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum to reach a broad spectrum of clients. Its extensive client base includes patients, clinicians, hospitals, integrated delivery networks, health plans, employers, and other direct healthcare entities. Delivery of these services is facilitated through a robust network comprising laboratories, patient service centers, in-office phlebotomists, call centers, and mobile health professionals including paramedics and nurses. Additionally, the company provides risk assessment services for the life insurance industry and offers comprehensive information technology solutions to healthcare organizations and clinicians.